Does Medicare Cover GLP-1 Medications in 2026?

Yes, but only in specific ways. As of July 1, 2026, a new program called the Medicare GLP-1 Bridge lets some people get Wegovy, Zepbound, or Foundayo for $50 a month, even if you’re only using it for weight loss. Outside that program, standard Medicare Part D still only covers GLP-1 drugs when they’re prescribed for something other than weight loss, like type 2 diabetes or sleep apnea. So does Medicare cover GLP-1 drugs for you specifically? It depends on your BMI, your health conditions, and which plan you’re in. Let’s get into it.

Quick Verdict

The Medicare GLP-1 Bridge is for you if: you have Medicare Part D or a Medicare Advantage plan with drug coverage, and you have a BMI of 35 or higher (or 30+ with a related health issue, or 27+ with prediabetes, a past heart attack, stroke, or PAD).

Skip it if: you already have type 2 diabetes, moderate to severe sleep apnea, or MASH (a liver condition). You don’t need the Bridge; you should already be covered under regular Part D for those.

Current price if you qualify: $50 a month, flat, no matter your income or dose. That price comes straight from Medicare.gov and won’t go up.

The Short Answer for 2026

For years, the answer to “does Medicare cover GLP-1” for weight loss was a hard no. That changed on July 1, 2026. CMS rolled out the Medicare GLP-1 Bridge, a temporary program that runs through December 31, 2027. It’s not part of your regular Part D benefit. It sits outside it, with its own rules and its own $50 copay.

Here’s the thing, though. Not everyone gets in. And even if you do, the $50 payment doesn’t count toward your deductible or your yearly out-of-pocket cap. So it’s a good deal, but it’s a separate deal.

What Is the Medicare GLP-1 Bridge Program, Really?

Think of it as a pilot program, not a permanent fix. Medicare wanted to help people afford weight loss drugs without blowing up the whole Part D budget, so they built a side door.

Who Qualifies

You need to be enrolled in a standalone Part D plan or a Medicare Advantage plan with drug coverage. Then your BMI and health history decide which tier you fall into:

• BMI of 35 or higher. You qualify automatically. No extra condition needed.
• BMI of 30 or higher, plus one of these: heart failure with preserved ejection fraction, uncontrolled high blood pressure (on two or more meds and still high), or chronic kidney disease stage 3a or worse.
• BMI of 27 or higher, plus prediabetes, a previous heart attack, a previous stroke, or peripheral artery disease.

One detail people miss: your BMI is checked at the point you started GLP-1 therapy, not necessarily today. So if you began the medication in 2024 at a BMI of 37 and you’re down to 34 now, your doctor can still attest you met the bar when you started.

Your doctor has to submit a prior authorization to a central CMS processor, not your regular Part D plan, and certify you’re pairing the drug with diet and exercise changes. Once that’s approved, you don’t need to reapply for every refill, unless you switch medications.

What’s Covered, and What Isn’t

The program covers three GLP-1 medications for weight management only: Foundayo (the pill), Wegovy (both the injection and the tablet), and Zepbound, but only the KwikPen. Zepbound single-dose vials and single-dose pens are not part of the program, so if you’re getting a vial, this doesn’t apply to you.

When It Ends

December 31, 2027. After that, CMS has floated a longer-term replacement called the BALANCE Model, but it’s not locked in yet. If you’re relying on the Bridge, keep an eye on updates, because this is a pilot, not a guarantee.

What If You Don’t Qualify for the Bridge?

A lot of readers are going to land in this bucket, and that’s okay; you’ve still got real options.

If you have type 2 diabetes, sleep apnea, or MASH, ask your doctor to bill your prescription through your regular Part D plan instead of the Bridge. That’s the coverage pathway that’s actually been around longer, and it often comes with lower copays than paying cash.

If none of that applies to you and your BMI doesn’t clear the Bridge thresholds, you’re looking at self-pay. That’s where the brand comparisons below come in. Kind of a pain, but there are real ways to bring the price down.

[link: Medicare GLP-1 Bridge Eligibility Checklist]

Brand Reviews: Self-Pay Options If Medicare Doesn’t Cover You

LillyDirect (Zepbound)

What it offers: Zepbound, the tirzepatide shot made by Eli Lilly, sold as either a single-dose vial or a single-patient-use KwikPen.

Current price: Straight from Lilly’s own Zepbound coverage page, self-pay pricing is $299 a month for the 2.5 mg starting dose, $399 a month for 5 mg, and $449 a month for the 7.5 mg through 15 mg doses if you refill within 45 days of your last order. Miss that window and the price jumps back up to $499 to $699 depending on dose.

Insurance angle: This is the confusing part, so I’ll be straight with you. Lilly’s savings card language explicitly excludes Medicare, Medicaid, and other government insurance. But the $299 to $449 self-pay pricing is meant for cash-pay customers generally, and multiple pharmacy sources say Medicare beneficiaries can use it as long as they’re paying cash and not billing the purchase to Medicare. Lilly’s own terms and conditions are honestly a little tangled on this point, so if you’re on Medicare, call LillyDirect support before you order to confirm your specific situation.

How signup works: You get a prescription from your own doctor or an independent provider through LillyDirect, then order online for home delivery or Walmart pickup.

How to cancel: No subscription lock-in; you just don’t reorder. There’s no membership fee sitting on top of the medication price.

Common complaints: People get tripped up by the 45-day refill rule. Miss it by even a few days and your price resets to full rate.

Who should use it: Anyone who specifically wants Zepbound and wants to buy direct from the manufacturer instead of going through a middleman telehealth company.

Who should skip it: Anyone on Medicare who hasn’t yet confirmed eligibility directly with Lilly. Don’t guess here, ask them first.

NovoCare (Wegovy)

What it offers: Wegovy, Novo Nordisk’s semaglutide shot and pill, direct from the manufacturer’s own pharmacy channel.

Current price: According to novocare.com, the Wegovy pen runs $349 a month for standard doses (0.25 mg through 2.4 mg) and $399 a month for the HD 7.2 mg pen. New patients get an introductory rate of $199 a month for their first two fills of the 0.25 mg or 0.5 mg starting doses, an offer that’s set to run through December 31, 2026. The Wegovy tablet is cheaper: $149 a month for the 1.5 mg and 4 mg doses, though the 4 mg tablet price is only guaranteed through August 31, 2026; after that it moves to $199.

Insurance angle: With commercial insurance, some patients pay as little as $25 a month using Novo’s savings card, but the card’s own terms say plainly, government beneficiaries excluded. That means Medicare and Medicaid patients can’t use the $25 card. You can still buy at the self-pay cash price, though.

How signup works: A licensed provider writes the prescription, then NovoCare Pharmacy ships it to your door, free shipping included.

How to cancel: Pay as you go, no ongoing membership fee.

Common complaints: The pricing page has a lot of footnotes and asterisks, and the intro pricing windows shift often, so what you see today might change by your next refill.

Who should use it: People who specifically want brand-name Wegovy and want to skip a telehealth middleman’s markup.

Who should skip it: Anyone hoping for the $25 savings card price while on Medicare; that one’s off the table.

Hims (Weight Loss Membership)

What it offers: A telehealth membership that connects you to a provider and, if prescribed, a range of medications including brand-name Wegovy, Zepbound, and oral weight loss kits.

Current price: Per hims.com, the membership itself costs $39 for the first month, then renews at $149 a month, and medication is billed on top of that, separately. Oral medication kits start at $69 a month on a 10-month plan paid upfront. Across the full product lineup, Hims says medication pricing can range anywhere from $69 up to $1,899 a month depending on what’s prescribed.

Insurance angle: Hims doesn’t require insurance and markets itself as an insurance-free path, which also means it generally won’t bill Medicare for you.

How signup works: Online intake form, async provider review, then shipment if approved.

How to cancel: Cancel anytime, but canceling the membership also cancels your active medication plan.

Common complaints: In July 2026, the FTC filed a lawsuit against Hims & Hers over alleged deceptive billing and data sharing practices, which the company is disputing. Separately, Hims settled with Novo Nordisk back in March 2026 and largely stopped offering compounded semaglutide to new patients, shifting toward branded products instead. If you were drawn to Hims for cheap compounded semaglutide, that door has mostly closed.

Who should use it: People who want one app for consults, refills, and support, and who are comfortable with a membership fee stacked on top of medication cost.

Who should skip it: I’d skip this one if you’re specifically chasing the cheapest possible compounded option; that’s just not where Hims is positioned anymore.

Noom Med

What it offers: GLP-1 prescribing bundled with Noom’s behavior-change coaching app.

Current price: Noom’s own med page lists the program starting at $149. Their pricing blog adds more detail: the Microdose GLP-1Rx tier starts with an initial 3-week subscription plus 4 weeks of medication, then renews at $179 a month billed quarterly, with that pricing effective for new accounts as of July 27, 2026.

Insurance angle: Compounded tiers are cash-pay only. If Noom prescribes a branded medication like Wegovy or Zepbound instead, insurance billing may be possible, but that’s handled case by case.

How signup works: Health assessment, provider review, then shipment with ongoing app-based coaching.

How to cancel: Online self-serve cancellation through the app.

Common complaints: The tier names and pricing structure change often enough that people find it hard to know exactly what they’re being billed for month to month.

Who should use it: Anyone who actually wants the coaching and habit-tracking piece, not just the prescription.

Who should skip it: If you just want the cheapest medication with no coaching wrapper, this isn’t the leanest option out there.

[link: Best GLP-1 Programs page]

Quick Comparison

Pick LillyDirect or NovoCare if you want the medication straight from the company that makes it, with no membership fee layered on top. Pick Hims if you want an app-based experience with support built in. Pick Noom Med if the coaching piece actually matters to you and you’ll use it.

[link: Zepbound vs Wegovy Cost Comparison]

FAQ

Does Medicare cover GLP-1 drugs for weight loss without the Bridge program? No. Standard Medicare Part D still doesn’t cover GLP-1 drugs used purely for weight loss. It covers them for diabetes, sleep apnea, or MASH. The Bridge program is the only current path to weight-loss-specific coverage, and it’s temporary.

What happens to my Bridge coverage after December 31, 2027? Right now, nobody knows for sure. CMS has mentioned a follow-up program, but it’s not confirmed. If you’re on the Bridge, this is worth watching closely as 2027 approaches.

Can I use manufacturer savings cards if I’m on Medicare? Generally, no. Both Lilly’s and Novo Nordisk’s commercial savings cards explicitly exclude government beneficiaries. Self-pay cash pricing is a different thing, and Medicare patients can often use that, but always confirm directly with the pharmacy first.

Is Zepbound covered the same way as Wegovy under the Bridge? Not exactly. The Bridge only covers the Zepbound KwikPen, not the single-dose vial or single-dose pen. Wegovy is covered in both injection and tablet form.

Do I need a diagnosis besides being overweight to qualify? Not always. If your BMI is 35 or higher, you qualify on BMI alone. Below that, you need a qualifying condition like prediabetes, uncontrolled blood pressure, or a history of heart attack or stroke.

My Honest Take

I’ll be honest with you, the Bridge program is a genuinely useful thing, and it’s the first real crack in Medicare’s wall against covering weight-loss-only GLP-1s. But it’s temporary; it has real BMI and condition requirements, and it explicitly excludes Zepbound vials and pens. If you don’t qualify, you’re not out of options; you’re just paying self-pay prices like everyone else without insurance. Talk to your doctor about whether the Bridge fits your situation, and if it doesn’t, compare the brand-direct prices above before you sign up for anything. Always talk with your doctor about which medication and dose actually make sense for you; this article can point you toward the numbers, but it can’t replace that conversation.